THE most common type of brain cancer in adults, glioblastoma, should be treated as two diseases not one, it now appears.
Glioblastoma patients whose cancers carry a mutation in a gene called IDH1 are 20 years younger than those without the mutation, on average. Cancers carrying the mutation are also less aggressive: people with this type of the disease had a median survival time of 3.8 years after diagnosis, compared with 1.1 years for those without it (Science, ).
While no existing drugs target IDH1, patients with this mutation may respond differently to the drugs that are…
